Sponsored
Sponsored
Media Summary: Michael Yee of Jefferies joins Closing Bell to discuss biotech stocks and why shares of CNBC's Meg Tirrell joins 'Squawk on the Street' to discuss Comprehensive cross-platform coverage of the U.S. market close on Bloomberg Television, Bloomberg Radio, and YouTube with ...

Moderna Downsizing Investments In Late - Detailed Analysis & Overview

Michael Yee of Jefferies joins Closing Bell to discuss biotech stocks and why shares of CNBC's Meg Tirrell joins 'Squawk on the Street' to discuss Comprehensive cross-platform coverage of the U.S. market close on Bloomberg Television, Bloomberg Radio, and YouTube with ... ModernaCEO Yahoo Finance's Aikiko Fujita, Zack Guzman, and Aikiko Fujita spoke with CNBC's Jim Cramer and the 'Squawk on the Street' team react to news from

Photo Gallery

Moderna downsizing investments in late-stage vaccine trials amid U.S. skepticism
Moderna stock plunge linked to 'overly high expectations,' strategist says
Moderna misses on earnings as supply constraints hinder COVID vaccine deliveries
Moderna stock down after positive booster news
Moderna asks investors to wait for full data on flu vaccine amid selloff
Moderna forecasts $17-22 billion in sales for 2022
Moderna CEO: ‘80% chance that the world slowly goes back to normal for most people’
Moderna CEO explains why the company is going to cut $1.1 billion in costs by 2027
Moderna stock downgrade: Openheimer analyst discusses why he downgraded the stock to neutral
Moderna CEO: 'Excited' About Future Following 4Q Revenue
COVID-19 ‘is not leaving the planet,’ Moderna CEO says
Moderna: ‘Our concern is more in valuation’ with booster shots 'baked into the stock,' analyst says
View Detailed Profile
Moderna downsizing investments in late-stage vaccine trials amid U.S. skepticism

Moderna downsizing investments in late-stage vaccine trials amid U.S. skepticism

Pharmaceutical company

Moderna stock plunge linked to 'overly high expectations,' strategist says

Moderna stock plunge linked to 'overly high expectations,' strategist says

Moderna

Sponsored
Moderna misses on earnings as supply constraints hinder COVID vaccine deliveries

Moderna misses on earnings as supply constraints hinder COVID vaccine deliveries

Moderna

Moderna stock down after positive booster news

Moderna stock down after positive booster news

Michael Yee of Jefferies joins Closing Bell to discuss biotech stocks and why shares of

Moderna asks investors to wait for full data on flu vaccine amid selloff

Moderna asks investors to wait for full data on flu vaccine amid selloff

Moderna

Sponsored
Moderna forecasts $17-22 billion in sales for 2022

Moderna forecasts $17-22 billion in sales for 2022

CNBC's Meg Tirrell joins 'Squawk on the Street' to discuss

Moderna CEO: ‘80% chance that the world slowly goes back to normal for most people’

Moderna CEO: ‘80% chance that the world slowly goes back to normal for most people’

Moderna

Moderna CEO explains why the company is going to cut $1.1 billion in costs by 2027

Moderna CEO explains why the company is going to cut $1.1 billion in costs by 2027

Moderna

Moderna stock downgrade: Openheimer analyst discusses why he downgraded the stock to neutral

Moderna stock downgrade: Openheimer analyst discusses why he downgraded the stock to neutral

Moderna

Moderna CEO: 'Excited' About Future Following 4Q Revenue

Moderna CEO: 'Excited' About Future Following 4Q Revenue

Moderna

COVID-19 ‘is not leaving the planet,’ Moderna CEO says

COVID-19 ‘is not leaving the planet,’ Moderna CEO says

COVID19 #coronavirus #

Moderna: ‘Our concern is more in valuation’ with booster shots 'baked into the stock,' analyst says

Moderna: ‘Our concern is more in valuation’ with booster shots 'baked into the stock,' analyst says

Moderna

Moderna Sees Biggest One-Day Decline Since December - Beyond the Bell

Moderna Sees Biggest One-Day Decline Since December - Beyond the Bell

Comprehensive cross-platform coverage of the U.S. market close on Bloomberg Television, Bloomberg Radio, and YouTube with ...

Moderna CEO: 'We are going to need boosters starting this fall'

Moderna CEO: 'We are going to need boosters starting this fall'

ModernaCEO #Modernavaccines #vaccine Yahoo Finance's Aikiko Fujita, Zack Guzman, and Aikiko Fujita spoke with

Moderna founder: We put out the data we had available

Moderna founder: We put out the data we had available

Noubar Afeyan,

Moderna plans stock buyback, sales forecast unchanged

Moderna plans stock buyback, sales forecast unchanged

Moderna

Moderna stock dips despite blowout quarterly earnings

Moderna stock dips despite blowout quarterly earnings

Moderna

Jim Cramer on Moderna shares down: Investors should look at Moderna 'a little more kindly'

Jim Cramer on Moderna shares down: Investors should look at Moderna 'a little more kindly'

CNBC's Jim Cramer and the 'Squawk on the Street' team react to news from

Moderna posts EPS beat, revenue miss for the first quarter

Moderna posts EPS beat, revenue miss for the first quarter

CNBC's Meg Tirrell reports on

Why Moderna's delayed break-even goal may not even be possible

Why Moderna's delayed break-even goal may not even be possible

Shares of

Related Video Content

Pioneering mRNA technology - Moderna information

Apr 11, 2026 · Moderna's mission is to deliver the greatest possible impact to people through mRNA medicines. So,...

Moderna - Wikipedia information

Moderna, Inc. (/ məˈdɜːrnə / mə-DUR-nə) [4] is an American pharmaceutical and biotechnology company based in...

Moderna, Inc. (MRNA) Stock Price, News, Quote & History ... information

Find the latest Moderna, Inc. (MRNA) stock quote, history, news and other vital information to help you with your...

Moderna information

The authorization or approval status of the Moderna COVID 19 Vaccine (also known as COVID-19 Vaccine Moderna) varies...

Moderna | History, Innovation, Challenges, & Facts ... information

May 17, 2026 · Moderna, Inc. is a biotechnology company specializing in messenger RNA (mRNA) medicines and is best...

Sponsored